Gilead Sciences, Inc. (GILD) vs Immunome, Inc. (IMNM)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| GILD | IMNM | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Biotechnology |
| Size band | LARGE | MID |
| Listing | Nasdaq GS | Nasdaq CM |
| Country | United States | United States |
| Theme | pharmaceuticals-large-cap | oncology |
| Price and returns | ||
| Last close | $158.69 | $17.89 |
| Return · 1 week | +3.67% | +6.68% |
| Return · 1 month | +4.26% | −17.48% |
| Return · 3 months | +18.14% | −22.95% |
| Return · year to date | +31.24% | −14.07% |
| Return · 1 year | +33.35% | +7.77% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −1.13% | −40.49% |
| 52-week high | $160.51 | $30.06 |
| 52-week low | $114.02 | $14.64 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $196.77B | $2.11B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $847.37M | $19.33M |
| Employees | 17,000 | 247 |
| Valuation | ||
| Price to earnings · trailing | n/a (negative earnings) | n/a (negative earnings) |
| Price to earnings · forward | 15.64× | n/a (negative forward earnings) |
| Price to sales | 6.35× | 626.47× |
| Price to book | 16.37× | 4.27× |
| Enterprise value to EBITDA | 14.71× | n/a (negative EBITDA) |
| Enterprise value to revenue | 7.05× | 482.27× |
| PEG ratio | 2.31 | — |
| Earnings per share · trailing | -2.65 | -2.39 |
| Profitability | ||
| Gross margin | 79.59% | — |
| Operating margin | 33.68% | −5698.83% |
| Profit margin | −10.64% | — |
| Return on equity | −20.68% | −50.14% |
| Return on assets | 14.09% | −29.72% |
| Growth | ||
| Revenue growth | +10.20% | — |
| Balance sheet and payout | ||
| Debt / equity (%) | 223.47 | 0.63 |
| Current ratio | 1.27 | 21.68 |
| Dividend yield | 2.10% | — |
| Payout ratio | 43.46% | 0.00% |
| Trend and volatility | ||
| RSI · 14 | 61.88 | 35.38 |
| ADX · 14 | 22.95 | 37.82 |
| 50-day average | $149.25 | $23.22 |
| 200-day average | $139.06 | $22.54 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 2.60% | 4.74% |
The full GILD analysis
Everything this table leaves out for Gilead Sciences, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the GILD argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full GILD analysisThe full IMNM analysis
Everything this table leaves out for Immunome, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the IMNM argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full IMNM analysis